Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. - Wikidata - awgldk - TriplyDB

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.

http://www.wikidata.org/entity/Q35269067

about

Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Trial Watch: Adoptive cell transfer for oncological indications NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation Pathways and therapeutic targets in melanoma Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells NK cells in the tumor microenvironment.Manufacturing Natural Killer Cells as Medicinal Products HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.NKG2D CARs as cell therapy for cancer.NK cell-based immunotherapy for malignant diseases.Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.Classification of current anticancer immunotherapies Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.Tumor-Associated Glycans and Immune Surveillance Trial Watch: Adoptive cell transfer immunotherapy.Cytokine-induced killer (CIK) cells: from basic research to clinical translation.Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2.Cytokine-induced killer cells promote antitumor immunity An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid.Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

P2860

Q26771449-A63ECA56-1C6D-4D74-9C63-CB0B2C57892C Q26773135-79CBD885-AEDB-4534-9BEE-2F8E85667DB3 Q26774678-5D362E8B-1A43-4F2E-A383-32A274BF9D1D Q26785545-2CBBA6C7-F97C-4BCB-B050-F15639E8EF07 Q26863559-2BC4FF50-E4B1-4635-B60C-EADBAB76F961 Q26865736-1A681048-2B7D-49F1-97EA-469F318C2DDF Q27309991-28C60EA4-6BD5-4992-BE68-21B9D64AEB39 Q27692606-34AAE531-C69A-474A-BAB1-1EFEDB555F1E Q28069992-91CEB45C-02ED-40A4-B967-0E3EFC5BB53E Q28080547-82175823-2217-41D2-8554-D6FEDB51CC99 Q28081338-4F4D3582-4F3E-4916-B7BF-8F513A3D8B11 Q28266580-6F911D25-5A22-4914-AE77-8EDCCAAB05D3 Q31118586-597AB3B0-5ED8-4D98-9DD8-E9D49931DDA5 Q33595873-2C02F697-291E-4D2E-A9A1-9FB27FA27D77 Q33827433-C0EB1CDC-5E85-40A5-AE07-3A675D2F8095 Q33861833-207224D6-2831-4218-A9F5-AD3D8B10D301 Q34180695-3DE8E6B8-3467-4207-B3BF-0E7C2103BF9A Q34618454-6127D82B-0BAC-4170-940A-0B38DDD6FA4F Q34786615-94E33AC8-FAB2-44B9-8936-CBDF6F14A182 Q35149637-665D6D46-38EC-4433-BE3B-1A2C28E6BE09 Q35543911-CF03A579-92FB-4E74-88EC-32661D91D706 Q35600095-373F4D9B-0831-4C46-A69F-BFBD6C1A50CB Q35800831-3C26C6F8-C9F8-41E7-BDF8-01723FFF527C Q35890610-5AEDA6F8-C9E5-4B32-9404-BA7D0DC62C0E Q36057432-3D8CB7A8-FFEB-46C9-896B-A74FE7F527CF Q36121153-411D3D07-C2D2-4AF7-8E51-4C9DA35A4E4C Q36163212-739D7510-7138-44B4-8E1A-57B96CCA9F91 Q36245682-E51985EA-5705-4E10-8C6D-6DF15A838861 Q36478280-50D7A032-8916-48E3-9F35-8400EC4541F9 Q36711029-F8E75B8E-B430-4F24-AB16-CB301FF685C3 Q36741617-B63FCC2F-4E29-484A-971A-CA564EA9270F Q36787587-D50F1A75-0961-4159-9F52-013B06292278 Q36853857-4DADC79C-6667-4429-AF9F-240D22BB3886 Q36856792-3E1F772F-340B-464A-89AF-EFCFC6BF1795 Q36887833-91148D67-1526-40A7-B85A-9F3274F7132D Q36916476-B954ED56-0BE1-4A43-B489-61CA20E7A5F1 Q37222064-BF56FB84-B400-4C7F-BDF4-EBA1EC72D97F Q37222176-552CA9A5-29D0-4A9A-A9DD-6ED6E5F6394A Q37358942-CD5B8EFF-E9EB-461C-BC6F-4B99594FD726 Q37434670-F93CCB21-B627-49A1-804F-BE728A3AE9BB

P2860

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.

http://www.wikidata.org/entity/Q35269067

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Adoptive transfer of autologou ...... not mediate tumor regression.

@ast

Adoptive transfer of autologou ...... not mediate tumor regression.

@en

type

label

Adoptive transfer of autologou ...... not mediate tumor regression.

@ast

Adoptive transfer of autologou ...... not mediate tumor regression.

@en

prefLabel

Adoptive transfer of autologou ...... not mediate tumor regression.

@ast

Adoptive transfer of autologou ...... not mediate tumor regression.

@en

P1433

Q35269067-C1504B05-4916-45F5-95F7-8D33013C75B5

P1476

Q35269067-D3807806-2AC1-4C6F-80DC-B808EA7F25BF

P2093

Q35269067-0074F9B1-39AD-4917-9734-44F32A1AE949

Q35269067-1277D695-4B99-4618-9514-BBDF4DA86C26

Q35269067-6A019F88-9EA0-4F4A-B746-44035AC9449C

Q35269067-EA1D39CC-DA72-4EA2-8D7C-FCDF28DE15EE

P2860

Q35269067-059F4CC6-D7AD-447D-B16B-3624A27BC73A

Q35269067-22245D44-BD63-48FD-84FD-D73F9CD94E7A

Q35269067-2433B653-B76C-43AB-8AB4-C11E4B3007A8

Q35269067-2E3CD750-4B00-4729-84D4-BEA585FF868E

Q35269067-35F41149-6695-471B-9F2F-5A1AD24D30C8

Q35269067-3749D390-D61C-4AEA-8F68-9036EAA61953

Q35269067-3A9ECC48-4B19-4207-A6A5-646F3982ACCA

Q35269067-3BDCCE2B-2A7A-4AB2-963C-A4EB6356B65E

Q35269067-3BF4E695-619A-4C50-8F14-216C3D171D23

Q35269067-487BD370-194D-4CFE-97A1-5E578AB14186

P304

Q35269067-787EEC27-22C4-4C98-9182-BF09E13F05F9

P31

Q35269067-70EE83A9-E2AB-496B-96C0-CB1A67B4F4AF

P356

Q35269067-A3118EE7-7B5C-4738-9856-22769F849DC9

P407

Q35269067-59E1C45A-0F25-45A5-9154-B46D1E39EE08

P433

Q35269067-5638C4FD-C45E-4E49-8048-982F211BB3CD

P478

Q35269067-C8FB66E1-CD3C-4B22-9D07-309FF0155298

P577

Q35269067-3C422B55-1385-4778-B506-1E7834FE28C3

P698

Q35269067-29244FED-1FB5-4EFA-96C3-C1F46FEFC0EC

P932

Q35269067-C1093C3D-6D33-4279-BADC-773D9AD103A9

P356

1078-0432.CCR-11-1347

P1433

Clinical Cancer Research

P1476

Adoptive transfer of autologou ...... not mediate tumor regression.

@en

P2093

John P Riley

http://www.w3.org/2001/XMLSchema#string

Maria R Parkhurst

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression in patients after transfer of genetically engineered lymphocytes

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

Innate or adaptive immunity? The example of natural killer cells

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Tumor cell recognition by natural killer cells.

P304

6287-6297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1347

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21844012

http://www.w3.org/2001/XMLSchema#string

P932

3186830

http://www.w3.org/2001/XMLSchema#string